Advanced search
Publication Cover
Biotechnology & Biotechnological Equipment Volume 35, 2021 - Issue 1
Submit an article Journal homepage
612
Views
0
CrossRef citations to date
0
Altmetric
Articles

Prognostic value of plasmablastic morphology and p21, p53 and Cyclin D1 expression in myeloma cells: retrospective study of 122 patients with newly diagnosed multiple myeloma

Jurijs Nazarovsa Pathology Centre, Riga East University Hospital, Rīga, Latvia;b Pauls Stradins Clinical University Hospital, Pathology Institute, Rīga, Latvia;c Department of Pathology, Riga Stradins University, Rīga, LatviaCorrespondence[email protected]
,
Austra Breikšaa Pathology Centre, Riga East University Hospital, Rīga, Latvia;b Pauls Stradins Clinical University Hospital, Pathology Institute, Rīga, Latvia;d Department of Pathology, University of Latvia, Rīga, Latvia
,
Regīna Kleinac Department of Pathology, Riga Stradins University, Rīga, Latvia
,
Sandra Lejniecee Department of Internal Diseases, Riga Stradins University, Rīga, Latvia;f Hematology and Chemotherapy Clinic, Riga East University Hospital, Rīga, Latvia
,
Jūlija Voicehovskae Department of Internal Diseases, Riga Stradins University, Rīga, Latvia;g Renal Disease and Kidney Replacement Therapy Clinics, Riga East University Hospital, Rīga, Latvia
&
Georgi Momekovh Department of Pharmacology, Pharmacotherapy and Toxicology, Faculty of Pharmacy, Medical University of Sofia, Sofia, BulgariaORCID Iconhttps://orcid.org/0000-0003-2841-7089
ORCID Icon
Pages 1941-1947 | Received 12 Oct 2021, Accepted 08 Feb 2022, Published online: 03 Mar 2022

References

  • Castaneda O, Baz R. Multiple myeloma genomics – a concise review. Acta Med Acad. 2019;48(1):57–67.
  • Pildava S. 2012. Doctus database (in Latvian) on the World Wide Web [last accessed 2020 Jun 10]. Retrieved from https://www.doctus.lv/2012/7/multipla-mieloma
  • Greipp PR, San Miguel J, Durie BGM, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412–3420.
  • Subramanian R, Basu D, Dutta TK. Prognostic significance of bone marrow histology in multiple myeloma. Indian J Cancer. 2009;46(1):40–45.
  • Møller HE, Preiss BS, Pedersen P, et al. Clinicopathological features of plasmablastic multiple myeloma: a population-based cohort. APMIS: acta pathologica. APMIS. 2015;123(8):652–658.
  • Fulciniti M, Martinez-Lopez J, Senapedis W, et al. Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma. Blood. 2017;129(16):2233–2245.
  • Ohata M, Nakamura S, Fujita H, et al. Prognostic implications of p21 (Waf1/Cip1) immunolocalization in multiple myeloma. Biomed Res. 2005;26(3):91–98.
  • Jovanović KK, Escure G, Demonchy J, et al. Deregulation and targeting of TP53 pathway in multiple myeloma. Front Oncol. 2018;8:665.
  • Soussi T. The history of p53. A perfect example of the drawbacks of scientific paradigms. EMBO Rep. 2010;11(11):822–826.
  • Chen MH, Qi CX, Saha MN, et al. p53 nuclear expression correlates with hemizygous TP53 deletion and predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with lenalidomide. Am J Clin Pathol. 2012;137(2):208–212.
  • Lonial S, Durie B, Palumbo A, et al. Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives. Leukemia. 2016;30(3):526–535.
  • Padhi S, Varghese RG, Ramdas A. Cyclin D1 expression in multiple myeloma by immunohistochemistry: case series of 14 patients and literature review. Indian J Med Paediatr Oncol. 2013;34(4):283–291.
  • Yan S, Liu H, Liu Z, et al. CCN1 stimulated the osteoblasts via PTEN/AKT/GSK3β/cyclinD1 signal pathway in myeloma bone disease. Cancer Med. 2020;9(2):737–744.
  • Cook JR, Hsi ED, Worley S, et al. Immunohistochemical analysis identifies two cyclin D1+ subsets of plasma cell myeloma, each associated with favorable survival. Am J Clin Pathol. 2006;125(4):615–624.
  • Athanasiou E, Kaloutsi V, Kotoula V, et al. Cyclin D1 overexpression in multiple myeloma. A morphologic, immunohistochemical, and in situ hybridization study of 71 paraffin-embedded bone marrow biopsy specimensAm J Clin Pathol. 2001;116(4):535–542.
  • Dunphy CH, Nies MK, Gabriel DA. Correlation of plasma cell percentages by CD138 immunohistochemistry, cyclin D1 status, and CD56 expression with clinical parameters and overall survival in plasma cell myeloma. Appl Immunohistochem Mol Morphol. 2007;15(3):248–254.
  • Anwer F, Gee KM, Iftikhar A, et al. Future of personalized therapy targeting aberrant signaling pathways in multiple myeloma. Clin Lymphoma Myeloma Leuk. 2019;19(7):397–405.
  • Suarez-Londono JA, Rohatgi A, Antoine-Pepeljugoski C, et al. Aggressive presentation of plasmablastic myeloma. BMJ Case Rep. 2020;13(4):e234436.
  • Srija M, Zachariah PP, Unni VN, et al. Plasmablastic myeloma presenting as rapidly progressive renal failure in a young adult. Indian J Nephrol. 2014;24(1):41–44.
  • Lamb EJ, Levey AS, Stevens PE. The kidney disease improving global outcomes (KDIGO) guideline update for chronic kidney disease: evolution not revolution. Clin Chem. 2013;59(3):462–465.
  • Durie BGM, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36(3):842–854. ):
  • Flynt E, Bisht K, Sridharan V, et al. Prognosis, biology, and targeting of TP53 dysregulation in multiple myeloma. Cells. 2020;9(2):287.
  • Dhyani A, Machado-Neto JA, Favaro P, et al. ANKHD1 represses p21 (WAF1/CIP1) promoter and promotes multiple myeloma cell growth. Eur J Cancer. 2015;51(2):252–259.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.